Climb Bio (CLYM) Cash & Equivalents (2020 - 2026)

Climb Bio (CLYM) has 7 years of Cash & Equivalents data on file, last reported at $8.4 million in Q1 2026.

• Quarterly Cash & Equivalents fell 71.21% year-over-year to $8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.4 million (down 71.21% YoY) and the FY2025 annual result came in at $35.7 million, down 59.09% from the prior year.
• Cash & Equivalents eased to $8.4 million in Q1 2026, from $35.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $218.1 million in Q2 2024 to a low of $8.4 million in Q1 2026.
• A 5-year average of $69.9 million and a median of $35.7 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents jumped 762.33% — and 2025, when it tumbled 89.6%.
• Tracing CLYM's Cash & Equivalents over 5 years: stood at $43.6 million in 2022, then surged by 136.05% to $102.9 million in 2023, then decreased by 15.22% to $87.2 million in 2024, then slumped by 59.09% to $35.7 million in 2025, then sank by 76.58% to $8.4 million in 2026.
• The last three Cash & Equivalents figures came in at $8.4 million (Q1 2026), $35.7 million (Q4 2025), and $25.8 million (Q3 2025), per Business Quant data.